CD34 and Fabry disease: In a pilot safety study, we have targeted enriched CD34+ hematopoietic stem/progenitor cells (HSPCs) for lentivirus (LV)-mediated gene therapy in patients with Fabry disease (NCT02800070, Fig. 1).